Share on StockTwits

Shares of Actavis plc (NYSE:ACT) have received an average recommendation of “Buy” from the twenty-five brokerages that are presently covering the company, Stock Ratings Network reports. Four equities research analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $234.57.

Several analysts have recently commented on the stock. Analysts at Leerink Swann reiterated an “outperform” rating on shares of Actavis plc in a research note on Thursday. They now have a $260.00 price target on the stock, down previously from $269.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Actavis plc in a research note on Wednesday. They now have a $225.00 price target on the stock. Finally, analysts at Susquehanna raised their price target on shares of Actavis plc from $260.00 to $270.00 in a research note on Wednesday.

Actavis plc (NYSE:ACT) opened at 203.94 on Monday. Actavis plc has a one year low of $130.06 and a one year high of $230.77. The stock’s 50-day moving average is $217.7 and its 200-day moving average is $207.5. The company has a market cap of $35.526 billion and a P/E ratio of 542.02.

Actavis plc (NYSE:ACT) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.36 by $0.06. The company had revenue of $2.67 billion for the quarter, compared to the consensus estimate of $2.55 billion. During the same quarter in the previous year, the company posted $2.01 earnings per share. The company’s revenue for the quarter was up 34.0% on a year-over-year basis. Analysts expect that Actavis plc will post $13.29 EPS for the current fiscal year.

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.